{"id":63020,"date":"2026-04-29T01:03:46","date_gmt":"2026-04-28T23:03:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/"},"modified":"2026-04-29T01:03:46","modified_gmt":"2026-04-28T23:03:46","slug":"samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/","title":{"rendered":"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific"},"content":{"rendered":"
\n

INCHEON, Korea & SHANGHAI–(BUSINESS WIRE)–#ATLATL<\/a>–Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies have entered into a Memorandum of Understanding (MoU) on an open innovation program to accelerate early-stage biotech innovation in Asia-Pacific.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThrough this partnership, Samsung Bioepis aims to leverage ATLATL\u2019s innovative R&D network and expertise in the Asia-Pacific biotech sector to identify and support promising early-stage biotech companies and breakthrough technologies.<\/p>\n

\n\u201cExternal innovation is becoming increasingly important in drug development\u2014not only to identify and foster promising early-stage technologies and companies, but also to cultivate a broader innovation ecosystem,\u201d said Min Jeong Seo, Vice President and Leader of Open Innovation Team, at Samsung Bioepis. \u201cBy leveraging ATLATL\u2019s extensive network and ecosystem as one of the largest biotech incubation centers in the Asia-Pacific region, we believe strategic partnerships can help accelerate the translation of promising science into meaningful medicines for patients.\u201d<\/p>\n

\n\u201cATLATL connects early-stage science with the infrastructure and expertise needed for real-world translation,\u201d said Dr. PC Zhu, founder and CEO of ATLATL. \u201cThrough our integrated R&D ecosystem across Asia-Pacific, and in collaboration with Samsung Bioepis, we aim to accelerate the development of high-potential technologies and bring impactful therapies to patients more efficiently.\u201d<\/p>\n

\nAs part of this collaboration, Samsung Bioepis plans to launch the Innovation Prize, an open innovation program in partnership with ATLATL. Through this initiative, selected early-stage biotech companies will have the opportunity to reside at ATLATL\u2019s incubation center with access to world-class resources, infrastructure, and expertise to accelerate their growth and development.<\/p>\n

\nAbout Samsung Bioepis Co., Ltd.<\/span><\/b><\/p>\n

\nEstablished in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology. For more information, please visit www.samsungbioepis.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>.<\/b><\/p>\n

\nAbout ATLATL<\/span><\/b><\/p>\n

\nAs a global innovation platform for life science research and development, ATLATL has established research centers in Beijing, Shanghai, Shenzhen, Singapore, Hong Kong, and other strategic locations.<\/p>\n

\nATLATL provides clients with comprehensive research and development services covering various stages, including in vitro drug screening, in vivo disease model establishment, and efficacy evaluation. ATLATL also supports key applications such as large molecule, small molecule, nucleic acid drugs, gene and cell therapy, drug delivery, as well as cutting-edge fields like multi-omics, gene editing, organoids, and organ-on-a-chip. Additionally, ATLATL provides an outstanding experimental environment and professional operational management for scientific researchers.<\/p>\n

\nThrough in-depth cooperation with leading global enterprises and research institutions, ATLATL continuously integrates research and development resources and promotes the sharing of new technologies. With advanced systematic research and development models, ATLATL accelerates the engineering process of life sciences, enabling scientific research results to be rapidly and efficiently translated into clinical practice, and contributing to life science innovation and public health on a global level.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/span><\/b>
Anna Nayun Kim, nayun86.kim@samsung.com<\/a>
Yoon Kim, yoon1.kim@samsung.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

INCHEON, Korea & SHANGHAI–(BUSINESS WIRE)–#ATLATL–Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies have entered into a Memorandum of Understanding (MoU) on an open innovation program to accelerate early-stage biotech innovation in Asia-Pacific. Through this partnership, Samsung … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-63020","6":"format-standard","7":"category-industry"},"yoast_head":"\nSamsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"INCHEON, Korea & SHANGHAI–(BUSINESS WIRE)–#ATLATL–Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies have entered into a Memorandum of Understanding (MoU) on an open innovation program to accelerate early-stage biotech innovation in Asia-Pacific. Through this partnership, Samsung ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T23:03:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260428924789\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific\",\"datePublished\":\"2026-04-28T23:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/\"},\"wordCount\":564,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260428924789\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/\",\"name\":\"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260428924789\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\",\"datePublished\":\"2026-04-28T23:03:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260428924789\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260428924789\\\/en\\\/608568\\\/22\\\/Samsung_Bioepis_Logo_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/","og_locale":"en_US","og_type":"article","og_title":"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific - Pharma Trend","og_description":"INCHEON, Korea & SHANGHAI–(BUSINESS WIRE)–#ATLATL–Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies have entered into a Memorandum of Understanding (MoU) on an open innovation program to accelerate early-stage biotech innovation in Asia-Pacific. Through this partnership, Samsung ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/","og_site_name":"Pharma Trend","article_published_time":"2026-04-28T23:03:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260428924789\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific","datePublished":"2026-04-28T23:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/"},"wordCount":564,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260428924789\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/","url":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/","name":"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260428924789\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","datePublished":"2026-04-28T23:03:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260428924789\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260428924789\/en\/608568\/22\/Samsung_Bioepis_Logo_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/samsung-bioepis-and-atlatl-sign-memorandum-of-understanding-mou-to-accelerate-early-stage-biotech-innovation-in-asia-pacific\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63020"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63020\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}